首页> 外文期刊>Medical dosimetry: official journal of the American Association of Medical Dosimetrists >Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal
【24h】

Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal

机译:二维放射疗法与调强放射疗法在晚期T期鼻咽癌治疗中的剂量学比较:减少或多于治疗计划中的脑干和脊髓高危器官

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study is to evaluate the deficiencies in target coverage and organ protection of 2-dimensional radiation therapy (2DRT) in the treatment of advanced T-stage (T3-4) nasopharyngeal carcinoma (NPC), and assess the extent of improvement that could be achieved with intensity modulated radiation therapy (IMRT), with special reference to of the dose to the planning organ-at-risk volume (PRV) of the brainstem and spinal cord. A dosimetric study was performed on 10 patients with advanced T-stage (T3-4 and N0-2) NPC. Computer tomography (CT) images of 2.5-mm slice thickness of the head and neck were acquired with the patient immobilized in semi-extended-head position. A 2D plan based on Ho's technique, and an IMRT plan based on a 7-coplanar portals arrangement, were established for each patient. 2DRT was planned with the field borders and shielding drawn on the simulator radiograph with reference to bony landmarks, digitized, and entered into a planning computer for reconstruction of the 3D dose distribution. The 2DRT and IMRT treatment plans were evaluated and compared with respect to the dose-volume histograms (DVHs) of the targets and the organs-at-risk (OARs), tumor control probability (TCP), and normal tissue complication probabilities (NTCPs). With IMRT, the dose coverage of the target was superior to that of 2DRT. The mean minimum dose of the GTV and PTV were increased from 33.7 Gy (2DRT) to 62.6 Gy (IMRT), and 11.9 Gy (2DRT) to 47.8 Gy (IMRT), respectively. The D(95) of the GTV and PTV were also increased from 57.1 Gy (2DRT) to 67 Gy (IMRT), and 45 Gy (2DRT) to 63.6 Gy (IMRT), respectively. The TCP was substantially increased to 78.5% in IMRT. Better protection of the critical normal organs was also achieved with IMRT. The mean maximum dose delivered to the brainstem and spinal cord were reduced significantly from 61.8 Gy (2DRT) to 52.8 Gy (IMRT) and 56 Gy (2DRT) to 43.6 Gy (IMRT), respectively, which were within the conventional dose limits of 54 Gy for brainstem and of 45 Gy for spinal cord. The mean maximum doses deposited on the PRV of the brainstem and spinal cord were 60.7 Gy and 51.6 Gy respectively, which were above the conventional dose limits. For the chiasm, the mean dose maximum and the dose to 5% of its volume were reduced from 64.3 Gy (2DRT) to 53.7 Gy (IMRT) and from 62.8 Gy (2DRT) to 48.7 Gy (IMRT), respectively, and the corresponding NTCP was reduced from 18.4% to 2.1%. For the temporal lobes, the mean dose to 10% of its volume (about 4.6 cc) was reduced from 63.8 Gy (2DRT) to 55.4 Gy (IMRT) and the NTCP was decreased from 11.7% to 3.4%. The therapeutic ratio for T3-4 NPC tumors can be significantly improved with IMRT treatment technique due to improvement both in target coverage and the sparing of the critical normal organ. Although the maximum doses delivered to the brainstem and spinal cord in IMRT can be kept at or below their conventional dose limits, the maximum doses deposited on the PRV often exceed these limits due to the close proximity between the target and OARs. In other words, ideal dosimetric considerations cannot be fulfilled in IMRT planning for T3-4 NPC tumors. A compromise of the maximal dose limit to the PRV of the brainstem and spinal cord would need be accepted if dose coverage to the targets is not to be unacceptably compromised. Dosimetric comparison with 2DRT plans show that these dose limits to PRV were also frequently exceeded in 2DRT plans for locally advanced NPC. A dedicated retrospective study on the incidence of clinical injury to neurological organs in a large series of patients with T3-4 NPC treated by 2DRT may provide useful reference data in exploring how far the PRV dose constraints may be relaxed, to maximize the target coverage without compromising the normal organ function.
机译:这项研究的目的是评估治疗晚期T期(T3-4)鼻咽癌(NPC)的二维放射疗法(2DRT)在靶标覆盖范围和器官保护方面的不足,并评估改善的程度这可以通过调强放射治疗(IMRT)来实现,特别要注意脑干和脊髓的计划性器官风险体积(PRV)的剂量。对10例晚期T期(T3-4和N0-2)NPC患者进行了剂量学研究。将患者固定在半张开的头部位置上,获取头颈部厚度为2.5毫米的计算机断层扫描(CT)图像。为每位患者建立了基于Ho技术的2D计划和基于7个共面门户结构的IMRT计划。计划了2DRT,并参照骨骼标志在模拟器X射线照片上绘制了场边界和屏蔽,将其数字化,然后输入到计划计算机中以重建3D剂量分布。对2DRT和IMRT治疗计划进行了评估,并比较了靶标的剂量-体积直方图(DVH)和高危器官(OAR),肿瘤控制概率(TCP)和正常组织并发症概率(NTCP) 。使用IMRT,靶标的剂量覆盖范围优于2DRT。 GTV和PTV的平均最小剂量分别从33.7 Gy(2DRT)增加到62.6 Gy(IMRT),从11.9 Gy(2DRT)增加到47.8 Gy(IMRT)。 GTV和PTV的D(95)也分别从57.1 Gy(2DRT)增加到67 Gy(IMRT),从45 Gy(2DRT)增加到63.6 Gy(IMRT)。在IMRT中,TCP显着提高到78.5%。使用IMRT还可以更好地保护关键的正常器官。交付给脑干和脊髓的平均最大剂量分别从61.8 Gy(2DRT)降至52.8 Gy(IMRT)和56 Gy(2DRT)降至43.6 Gy(IMRT),均在传统剂量上限54内脑干为Gy,脊髓为45 Gy。沉积在脑干和脊髓PRV上的平均最大剂量分别为60.7 Gy和51.6 Gy,高于常规剂量限值。对于黑斑病,最大剂量和最大剂量的平均剂量分别从64.3 Gy(2DRT)降至53.7 Gy(IMRT)和62.8 Gy(2DRT)降至48.7 Gy(IMRT),并相应降低NTCP从18.4%减少到2.1%。对于颞叶,平均剂量至其体积的10%(约4.6 cc)从63.8 Gy(2DRT)降低至55.4 Gy(IMRT),NTCP从11.7%降低至3.4%。通过IMRT治疗技术可以显着提高T3-4 NPC肿瘤的治疗率,这是因为靶标覆盖率和关键正常器官的保留均得到改善。尽管在IMRT中传递至脑干和脊髓的最大剂量可以保持在常规剂量限值或以下,但由于靶标和OAR之间的紧密距离,PRV上沉积的最大剂量通常会超过这些限值。换句话说,IMRT计划中的T3-4 NPC肿瘤不能满足理想的剂量学考虑。如果不希望损害靶标的剂量范围,则需要接受对脑干和脊髓PRV的最大剂量限值的折衷。与2DRT计划的剂量学比较表明,局部先进的NPC在2DRT计划中也经常超过PRV的这些剂量限制。一项专门的回顾性研究对接受2DRT治疗的一系列T3-4 NPC患者的神经器官临床损伤发生率进行了回顾性研究,可为探索PRV剂量限制可以放宽多大程度,以最大程度地扩大目标覆盖范围而无需提供参考数据。损害正常的器官功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号